User: Guest  Login
Title:

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.

Document type:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Article
Author(s):
Boeck, S; Weigang-Köhler, K; Fuchs, M; Kettner, E; Quietzsch, D; Trojan, J; Stötzer, O; Zeuzem, S; Lordick, F; Köhne, CH; Kröning, H; Steinmetz, T; Depenbrock, H; Heinemann, V
Abstract:
BACKGROUND: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). PATIENTS AND METHODS: In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on single-agent Gem or a Gem-containing regimen received pemetrexed 500 mg/m(2) as a 10-min infusion every 3 weeks until disease progression or occurrence of unacceptable toxicity. The primary end point was the 3-month su...     »
Journal title abbreviation:
Ann Oncol
Year:
2007
Journal volume:
18
Journal issue:
4
Pages contribution:
745-51
Language:
eng
Fulltext / DOI:
doi:10.1093/annonc/mdl463
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/17229775
Print-ISSN:
0923-7534
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX